Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine

Schizophrenia Research

Volumn 156, Issue 1, 2014, Pages 1-8

  O'Connell, Kara E ^a,b,c   Thakore, Jogin ^b   Dev, Kumlesh K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b St Vincent's Hospital Ireland   (Ireland)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics; Biomarker; Clozapine; Cytokines; Immune system; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; NEUROLEPTIC AGENT;

ADIPOCYTE; ADULT; AGE; AGED; ARTICLE; BODY MASS; CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCHIZOPHRENIA; SEX DIFFERENCE; TIME TO TREATMENT; BLOOD; MIDDLE AGED; NONPARAMETRIC TEST; PSYCHOLOGICAL RATING SCALE; SEXUAL DEVELOPMENT; STATISTICS; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CLOZAPINE; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEX CHARACTERISTICS; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84899937321     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.03.020     Document Type: Article

References (42)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR 1994, American Psychiatric Press, Washington, DC. 4th rev. ed.
2. Andreasen N. Negative symptoms in schizophrenia. Arch. Gen. Psychiatry 1982, 39(7):784-788.
3. Barnett A.H., Mackin P., Chaudhry I., Farooqi A., Gadsby R., Heald A., Hill J., Millar H., Peveler R., Rees A., Singh V., Taylor D., Vora J., Jones P.B. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J. Psychopharmacol. 2007, 21(4):357-373.
4. Beumer W., Drexhage R.C., De Wit H., Versnel M.A., Drexhage H.A., Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012, 37(12):1901-1911.
5. Borovcanin M., Jovanovic I., Radosavljevic G., Djukic Dejanovic S., Bankovic D., Arsenijevic N., Lukic M.L. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J. Psychiatr. Res. 2012, 46(11):1421-1426.
6. Chatterjee S., Szustakowski J.D., Nanguneri N.R., Mickanin C., Labow M.A., Nohturfft A., Dev K.K., Sivasankaran R. Identification of novel genes and pathways regulating SREBP transcriptional activity. PLoS One 2009, 4(4):e5197.
7. Contreras-Shannon V., Heart D.L., Paredes R.M., Navaira E., Catano G., Maffi S.K., Walss-Bass C. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One 2013, 8(3):e59012.
8. Covell N.H., Weissman E.M., Essock S.M. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr. Bull. 2004, 30(2):229-240.
9. Di Nicola M., Cattaneo A., Hepgul N., Di Forti M., Aitchison K.J., Janiri L., Murray R.M., Dazzan P., Pariante C.M., Mondelli V. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013, 31(7):90-95.
10. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. Nacetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert. Opin. Biol. Ther. 2008, 8(12):1955-1962.
11. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert. Rev. Neurother. 2010, 10(1):59-76.
12. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35(3):528-548.
13. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2013, 8(2):206-214.
14. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56(4):1010-1013.
15. Głowińska B., Urban M. Selected cytokines (Il-6, Il-8, Il-10, MCP-1, TNF-alpha) in children and adolescents with atherosclerosis risk factors: obesity, hypertension, diabetes. Wiad. Lek. 2003, 56:109-116.
16. Insel T.R. Rethinking schizophrenia. Nature 2010, 468(7321):187-193.
17. Khairova R.A., Machado-Vieira R., Du J., Manji H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 2009, 12(4):561-578.
18. Kim Y., Zerwas S., Trace S.E., Sullivan P.F. Schizophrenia genetics: where next?. Schizophr. Bull. 2011, 37(3):456-463.
19. Kinney D.K., Hintz K., Shearer E.M., Barch D.H., Riffin C., Whitley K., Butler R. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med. Hypotheses 2010, 74(3):555-563.
20. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(2):S114-S124.
21. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71(5):520-527.
22. Lacourt T.E., Houtveen J.H., Smeets H.M., Lipovsky M.M., van Doornen L.J. Infection load as a predisposing factor for somatoform disorders: evidence from a Dutch General Practice Registry. Psychosom. Med. 2013, 75(8):759-764.
23. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
24. Müller N., Schwarz M.J. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert. Rev. Neurother. 2006, 6(7):1017-1038.
25. Müller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(2):97-106.
26. Müller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Möller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121(1-3):118-124.
27. Nosé M., Barbui C., Gray R., Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br. J. Psychiatry 2003, 183:197-206.
28. O'Connell K., Thakore J., Dev K.K. Levels of S100B are raised in female patients with schizophrenia. BMC Psychiatry 2013, 13(5):146.
29. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
30. Pham M.N., Hawa M.I., Pfleger C., Roden M., Schernthaner G., Pozzilli P., Buzzetti R., Scherbaum W.A., Seissler J., Kolb H., Hunter S., Leslie R.D., Schloot N.C. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4. Diabetologia 2011, 54(7):1630-1638. Action, LADA Study Group.
31. Pollmacher T., Haack M., Schuld A., Kraus T., Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J. Psychiatry Res. 2000, 34(6):369-382.
32. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
33. Røge R., Møller B.K., Andersen C.R., Correll C.U., Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?. Schizophr. Res. 2012, 140(1-3):204-213.
34. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., McAllister G., Spain M., Barnes A., van Beveren N.J., Baron-Cohen S., Steiner J., Torrey F.E., Yolken R.H., Bahn S. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2012, 17(5):494-502.
35. Shrestha R., Millington O., Brewer J., Dev K.K., Bushell T.J. Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways. Neuropharmacology 2014, 76(A):184-193.
36. Soczynska J.K., Kennedy S.H., Goldstein B.I., Lachowski A., Wol-deyohannes H.O., McIntyre R.S. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. Neurotoxicology 2009, 30:497-521.
37. Steiner J., Bogerts B., Schroeter M.L., Bernstein H.G. S100B protein in neurodegenerative disorders. Clin. Chem. Lab. Med. 2011, 49(3):409-424.
38. Sugino H., Futamura T., Mitsumoto Y., Maeda K., Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):303-307.
39. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010, 64(3):217-230.
40. Williams L., Newton G., Roberts K., Finlayson S., Brabbins C. Clozapine-resistant schizophrenia: a positive approach. Br. J. Psychiatry 2002, 181:184-187.
41. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
42. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148:209-214.